RxDoctor Payments DataLook up a doctor →

Robert Griffin

Wyomissing, PANPI 1528064318

Payments from drug & device makers

$675,040in general payments, 2019–2025

Across 430 payments — averaging $1569.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$276K
  • Gilead$201K
  • Astrazeneca UK Limited$66K
  • Pfizer$31K
  • Merck$28K
  • E.r. Squibb & Sons, L.L.C.$26K
  • plus $45K from 24 others
$6,966in research payments, 2019–2025

Across 6 payments — averaging $1161.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$6K
  • Eli Lilly Export S.A. Puerto Rico Branch$495

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly37$276,276
Gilead73$201,066
Astrazeneca UK Limited11$66,345
Pfizer57$31,438
Merck4$28,343
E.r. Squibb & Sons, L.L.C.18$26,194
Astrazeneca AB1$23,429
GSK15$7,233
Sanofi US Services Inc.4$4,112
AbbVie19$3,724
EMD Serono, Inc.1$2,348
Planmeca USA, Inc.1$1,326
Novartis31$563
Amgen(2 entities)30$460
Johnson & Johnson(2 entities)17$362
Genentech USA, Inc.23$351
Sanofi11$225
UCB, Inc.14$210
Lilly USA, LLC9$180
Radius Health, Inc.7$161
Medexus Pharma, Inc.14$147
AstraZeneca(2 entities)10$139
Sobi, Inc6$109
Actelion Pharmaceuticals US, Inc.5$92
Ferring Pharmaceuticals Inc.2$45
Takeda Pharmaceuticals U.S.A., Inc.4$43
Bristol Myers Squibb3$40
Mallinckrodt Hospital Products Inc.1$34
Mallinckrodt Enterprises LLC1$27
Aurinia Pharma U.S., Inc.1$20

Where these figures come from

Is this you, or does something look wrong? →